OBJECTIVES The purpose of this study was to compare the long-term clinical outcomes of patients with chronic total occlusion (CTO) and well-developed collateral circulation treated with revascularization versus medical therapy.
patients with CTO has also increased due to improvements in device technology such as drug-eluting stents, dedicated guidewires, and microcatheters (5, 6) . However, high frequencies of failed PCI, perioperative mortality, and potential lethal complications related to revascularization still exist in patients with CTO (5) 
WELL-DEVELOPED COLLATERAL CIRCULATION.
Coronary angiography was reviewed by experienced interventional cardiologists blinded to patient data, and the extent of collateral flow was assessed according to the validated Rentrop classification scale (10) . The grades of collateral filling from the contralateral vessel were: 0 ¼ none; 1 ¼ filling of side branches of the artery to be dilated via collateral channels without visualization of the epicardial segment; 2 ¼ partial filling of the epicardial segment via collateral channels; and 3 ¼ complete filling of the epicardial segment of the artery to be dilated via collateral channels. We considered patients with well-developed collateral circulation to have Rentrop grade 3 collateral flow. After selection of these patients, we confirmed the Rentrop grades by reviewing the associated angiograms in all cases.
TREATMENT STRATEGY. All patients received antiplatelet therapy with aspirin at a dose of 81 to 325 mg/ day, or clopidogrel at 75 mg/day if aspirin intolerance was reported. All patients were taking 1 or more antianginal medications, including a long-acting beta-blocker, calcium-channel blocker, and isosorbide mononitrate, alone or in combination, along with either an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker as standard secondary prevention. All patients received a highdose statin alone or in combination with ezetimibe in order to reduce the low-density lipoprotein cholesterol level to a target level of 60 to 85 mg/dl (1.55 to 2.20 mmol/l). The dosages of all medications were maximized as allowed by heart rate, blood pressure, and side effects in the absence of justifiable relative contraindications.
Revascularization of CTOs was accomplished by
CABG or PCI with drug-eluting stent, and each revascularization strategy was selected as a treatment option based on the patient's and physician's preference. In a case of CABG for CTOs, arterial grafting with off-pump coronary artery bypass was the preferred technique. The surgical risk was assessed using the EuroSCORE (mean AE SD), and high surgical risk was defined as a EuroSCORE of $6 (11). PCI was performed using contemporary techniques such as bilateral injections; a specialized stiff, hydrophilic wire with a tapered tip; microcatheters; and a retrograde approach when available. The decision to pursue invasive treatment, the access site, type of drug-eluting stent, use of intravascular ultrasound, and use of glycoprotein IIb/IIIa receptor inhibitor were all left to the operator's discretion. All interventions and procedural anticoagulation were performed according to current standard guidelines.
All patients received loading doses of aspirin (300 mg) and clopidogrel (300 to 600 mg) before PCI unless they had previously received these antiplatelet 
Treatment of CTO With Abundant Collateral iables. In the propensity score-matched population, risk reductions were compared using a conditional Cox regression model (14) . All tests were 2-tailed, and p < 0.05 was considered to be statistically significant. Table 1 . Compared with the medication group, the revascularization group was younger and had significantly lower prevalence of previous PCI but higher prevalence of dyslipidemia and ACS. The left ventricular ejection fraction was higher in the revascularization group. Angiographic analysis showed that CTO of the left anterior descending coronary artery, multiple CTOs, and proximal to mid CTO were noted more frequently in the revascularization group. The SYNTAX score (15) was higher in the revascularization group ( Table 2) . Values are n (%) or mean AE SD. *"CTO of the proximal to middle portions of the vessel" has been abbreviated as "Proximal to mid CTO."
CTO ¼ coronary chronic total occlusion; LAD ¼ left anterior descending artery; LCx ¼ left circumflex artery; LM ¼ left main coronary artery; RCA ¼ right coronary artery. Table 4 , Figures 2A and 2B ).
SUBGROUP ANALYSIS OF THE REVASCULARIZATION
GROUP. The revascularization group was composed of the CABG subgroup (n ¼ 170, 34% of the revascularization group) and the PCI subgroup (n ¼ 332, 66%); there were no significant differences in clinical outcomes between the 2 subgroups with the exception of MACE, which was primarily driven by Values are n (%). *Adjusted covariates include age, ACS, CTO of LAD, multiple CTOs, previous PCI, and proximal to mid CTO. †Repeat revascularization included target vessel revascularization-PCI, non-target vessel revascularization-PCI, and coronary artery bypass grafting (CABG). ‡Major adverse cardiac events (MACE) included cardiac death, MI, and repeat revascularization with PCI or CABG.
CI ¼ confidence interval; HR ¼ hazard ratio; other abbreviations as in Tables 1 and 2 . Table 5) .
SUBGROUP ANALYSIS OF THE FAILED CTO-PCI
GROUP. Of 66 patients with failed CTO-PCI, 33 patients (50% of patients with failed CTO-PCI) were treated with medical therapy, 9 patients (13.6%) with CABG, and 24 patients (36.4%) with a reattempt at PCI. A total of 6 failed CTO-PCI patients (25% of the reattempted CTO-PCI patients) were successfully treated with reattempt PCI. Among 9 failed CTO-PCI patients treated with CABG, 4 patients emergently underwent CABG because of hypotension or sustained chest pain, and 5 patients electively underwent CABG several weeks later (Figure 3) . In the failed CTO-PCI patients, 4 all-cause deaths (6.1% of failed CTO-PCI patients), 2 cardiac deaths (3.0%), and no
MIs occurred during follow-up duration.
DISCUSSION
We investigated the long-term clinical outcomes of coronary revascularization versus medical therapy in patients with CTO and well-developed collateral circulation using a large dedicated registry. The primary finding of our study was that patients with CTO and well-developed collateral circulation who underwent revascularization had significantly lower risk of cardiac death, all-cause death, and MACE compared with those treated with medical therapy alone. Although this study was limited by its observational design, this is the first report specifically addressing the issue of revascularization and collateral circulation, and it evaluated the potential survival benefit related with the revascularization in those CTO patients.
Several studies have shown a survival benefit in patients with CTO who undergo successful PCI compared with those who undergo failed procedures, suggesting that survival depends on procedural success (17, 18) . However, these results are limited in their application, as it is difficult to predict the success of an intervention. In contrast to previous studies, we evaluated the clinical outcomes of overall treatment strategies (including medical therapy, CABG, successful PCI, or failed PCI, and so on) using an intent-to-treat analysis of a large, dedicated registry. Therefore, our Values are n (%). *Repeat revascularization included target vessel revascularization-PCI, non-target vessel revascularization-PCI, and CABG. †Major adverse cardiac events (MACE) included cardiac death, MI, and repeat revascularization with PCI or CABG.
Abbreviations as in Tables 1 and 3 . Jang et al.
Treatment of CTO With Abundant Collateral Values are n (%). *Adjusted covariates include DM, LVEF (%), and SYNTAX score. †Repeat revascularization included target vessel revascularization-PCI, non-target vessel revascularization-PCI, and coronary artery bypass grafting (CABG). ‡Major adverse cardiac events (MACE) included cardiac death, MI, and repeat revascularization with PCI or CABG.
DM ¼ diabetes mellitus; other abbreviations as in Tables 1 and 3 . choi@samsung.com.
